Xilio Therapeutics Launches Pre-Funded Warrant Offering

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 2h ago

0mins

XLO-1.11%

Should l Buy XLO?

Source: seekingalpha

Offering Size: Xilio Therapeutics is pricing an underwritten offering of approximately 74.8 million pre-funded warrants at $0.5349 each, aiming for gross proceeds of around $40 million, which underscores the company's ability to raise capital in the market.
Use of Proceeds: The net proceeds from this offering will be allocated towards advancing the development of its product candidates, working capital needs, and other general corporate purposes, indicating the company's commitment to future R&D and market opportunities.
Transaction Timeline: The offering is expected to close on or about February 13, 2026, reflecting the company's strategic planning in capital operations to ensure funding for future growth.
Market Reaction: Xilio Therapeutics' financing initiative may impact its stock performance, prompting investors to monitor subsequent market dynamics and the company's progress in product development.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy XLO?" and start using high-conviction signals backed by rigorous historical data.

XLO

$0.535+Infinity%1D

Analyst Views on XLO

About XLO

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Xilio Therapeutics Prices Pre-Funded Warrant Offering

7 hours agoNewsfilter

Offering Size: Xilio Therapeutics announced the pricing of pre-funded warrants at $0.5349 each for 74,780,300 shares, with expected gross proceeds of approximately $40 million, indicating strong market interest in the company's offerings.
Use of Proceeds: The net proceeds from this offering will be utilized to advance the development of product candidates and for working capital needs, highlighting the company's commitment to future R&D and market opportunities.
Investor Participation: The financing was led by existing investor Coastlands Capital and included participation from institutional investors like Gilead Sciences, reflecting strong market confidence and support for Xilio's strategic direction.
Underwriting Arrangement: Leerink Partners is acting as the sole bookrunner for the offering, ensuring professionalism and efficiency in the financing process, which also lays a solid foundation for future capital operations.